Aspire Biopharma Holdings, Inc, a developer of a multi-faceted patent-pending drug delivery technology, announced initiation of its phase 1 single-centre clinical study of its lead therapeutic ...

A clinical trial involving human participants is already in the works, aiming to further explore the therapeutic potential of low-dose opioids for treating social interaction deficits in ASD. The ...

Description The goal of the trial was to evaluate treatment with famotidine compared with placebo among patients taking low-dose aspirin. Hypothesis Famotidine would be more effective in ...

Phase 1 Study Design The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when administered ...

WASHINGTON—President Trump took aim at a low-pressure target: wimpy showers. Trump signed an executive order on Wednesday rolling back a federal regulation he has blamed for poor water pressure.

Phase 1 Study Design The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when ...

For prolonged antithrombotic treatment after percutaneous coronary intervention (PCI), clopidogrel monotherapy was more effective and at least as safe as aspirin monotherapy in a high-risk population, ...

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug ...

Aspire Biopharma (ASBP) announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation.

Aspire intends to request "fast track" approval on FDA application for its high-dose aspirin product HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings ...